Brainstorm Cell Therapeutics Inc.
BCLI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | -$0 | -$0 | -$0 |
| % Margin | 100% | – | – | – |
| R&D Expenses | $4 | $10 | $14 | $15 |
| G&A Expenses | $7 | $11 | $11 | $9 |
| SG&A Expenses | $7 | $11 | $11 | $9 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $11 | $21 | $25 | $25 |
| Operating Income | -$12 | -$21 | -$25 | -$25 |
| % Margin | -1,377.3% | – | – | – |
| Other Income/Exp. Net | $0 | $4 | $1 | $0 |
| Pre-Tax Income | $12 | -$17 | -$24 | -$24 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $12 | -$17 | -$24 | -$24 |
| % Margin | 1,369% | – | – | – |
| EPS | 2.19 | -4.48 | -9.93 | -10.09 |
| % Growth | 148.9% | 54.9% | 1.6% | – |
| EPS Diluted | 2.19 | -4.48 | -9.93 | -10.09 |
| Weighted Avg Shares Out | 5 | 4 | 2 | 2 |
| Weighted Avg Shares Out Dil | 5 | 4 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$11 | -$17 | -$24 | -$24 |
| % Margin | -1,331.7% | – | – | – |